全文获取类型
收费全文 | 9157篇 |
免费 | 483篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 128篇 |
儿科学 | 614篇 |
妇产科学 | 138篇 |
基础医学 | 801篇 |
口腔科学 | 177篇 |
临床医学 | 738篇 |
内科学 | 2491篇 |
皮肤病学 | 234篇 |
神经病学 | 495篇 |
特种医学 | 239篇 |
外科学 | 1264篇 |
综合类 | 205篇 |
预防医学 | 395篇 |
眼科学 | 327篇 |
药学 | 554篇 |
中国医学 | 15篇 |
肿瘤学 | 846篇 |
出版年
2023年 | 40篇 |
2021年 | 261篇 |
2020年 | 138篇 |
2019年 | 187篇 |
2018年 | 276篇 |
2017年 | 146篇 |
2016年 | 163篇 |
2015年 | 191篇 |
2014年 | 284篇 |
2013年 | 350篇 |
2012年 | 534篇 |
2011年 | 555篇 |
2010年 | 313篇 |
2009年 | 222篇 |
2008年 | 426篇 |
2007年 | 488篇 |
2006年 | 458篇 |
2005年 | 407篇 |
2004年 | 400篇 |
2003年 | 335篇 |
2002年 | 331篇 |
2001年 | 267篇 |
2000年 | 237篇 |
1999年 | 215篇 |
1998年 | 95篇 |
1997年 | 51篇 |
1996年 | 42篇 |
1995年 | 63篇 |
1993年 | 42篇 |
1992年 | 168篇 |
1991年 | 172篇 |
1990年 | 169篇 |
1989年 | 151篇 |
1988年 | 141篇 |
1987年 | 129篇 |
1986年 | 112篇 |
1985年 | 106篇 |
1984年 | 105篇 |
1983年 | 73篇 |
1982年 | 51篇 |
1981年 | 42篇 |
1980年 | 39篇 |
1979年 | 82篇 |
1978年 | 39篇 |
1977年 | 61篇 |
1974年 | 49篇 |
1973年 | 38篇 |
1972年 | 48篇 |
1970年 | 43篇 |
1969年 | 38篇 |
排序方式: 共有9661条查询结果,搜索用时 35 毫秒
1.
Paula M. Frew Raphiel Murden C. Christina Mehta Allison T. Chamberlain Alan R. Hinman Glen Nowak Judith Mendel Ann Aikin Laura A. Randall Allison L. Hargreaves Saad B. Omer Walter A. Orenstein Robert A. Bednarczyk 《Vaccine》2019,37(2):325-332
Objective
To develop a Vaccine Confidence Index (VCI) that is capable of detecting variations in parental confidence towards childhood immunizations centered on trust and concern issues that impact vaccine confidence.Methods
We used a web-based national poll of 893 parents of children <7?years in 2016 to assess the measures created for the Emory VCI (EVCI). EVCI measures were developed using constructs related to vaccine confidence identified by the U.S. National Vaccine Advisory Committee (i.e., “Information Environment”, “Trust”, “Healthcare Provider”, “Attitudes and Beliefs”, and “Social Norms”). Reliability for EVCI was assessed using Cronbach’s alpha. Using the variables related to each of the constructs, we calculated an overall EVCI score that was then assessed against self-reported childhood vaccine receipt using chi-square and the Cochrane-Armitage trend tests.Results
Respondents’ EVCI scores could range from 0 to 24, and the full range of values was observed in this sample (Mean?=?17.5 (SD 4.8)). EVCI scores were significantly different (p?≤?0.006 for all comparisons) between parents who indicated their child(ren) received routinely recommended vaccines compared with parents who indicated they had delayed or declined recommended immunizations. There was also a significant, consistent association between higher EVCI scores and greater reported vaccine receipt.Conclusions
We developed EVCI to reliably measure parental vaccine confidence, with individuals’ scores linked to parental vaccine-related attitudes, intentions, and behaviors. As such, EVCI may be a useful tool for future monitoring of both population and individual confidence in childhood immunization. 相似文献2.
3.
4.
Mehta Gautam U. Muelleman Thomas J. Brackmann Derald E. Gidley Paul W. 《Journal of neuro-oncology》2020,149(3):437-445
Journal of Neuro-Oncology - This study was performed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of the immunomodulatory agent, lenalidomide, when administered... 相似文献
5.
Diamantis I. Tsilimigras MD Rittal Mehta MPH Alfredo Guglielmi MD Francesca Ratti MD Hugo P. Marques MD Olivier Soubrane MD Vincent Lam MD George A. Poultsides MD Irinel Popescu MD Sorin Alexandrescu MD Guillaume Martel MD Tom Hugh MD Luca Aldrighetti MD Itaru Endo MD PhD Timothy M. Pawlik MD MPH PhD FACS FRACS 《Journal of surgical oncology》2020,122(5):955-963
6.
7.
Tej I Mehta Simcha Weissman Brian M Fung James H Tabibian 《World journal of hepatology》2020,12(4):116-124
Primary sclerosing cholangitis (PSC) is a chronic, progressive, hepatobiliary disease characterized by inflammation and fibrosis of the intra- and extra-hepatic bile ducts. Its natural history is one that generally progresses towards cirrhosis, liver failure, cholangiocarcinoma, and ultimately disease-related death, with a median liver transplantation-free survival time of approximately 15-20 years. However, despite its lethal nature, PSC remains a heterogenous disease with significant variability in outcomes amongst different regions of the world. There are also many regions where the outcomes of PSC have not been studied, limiting the overall understanding of this disease worldwide. In this review, we present the geoepidemiologic variations in outcomes of PSC, with a focus on survival pre- and post-liver transplantation as well as the concurrence of inflammatory bowel disease and hepatobiliary neoplasia. 相似文献
8.
9.
10.
Rachel A. Katzenellenbogen Joseph J. Carter Joshua E. Stern Melinda S. Butsch Kovacic Parinda A. Mehta Sharon L. Sauter Denise A. Galloway Rachel L. Winer 《Clinical and Vaccine Immunology : CVI》2015,22(4):413-420
Persons with Fanconi anemia (FA) are at risk for human papillomavirus (HPV)-associated cancers; however, their natural HPV exposure and infection rates are unknown as is the adequacy with which they mount antibodies to HPV vaccination. This study aimed to determine, in 62 persons with FA, the seroprevalence of skin and mucosal HPV types, the seroprevalence in individuals self-reporting a history of HPV vaccination, and the factors associated with HPV seropositivity. A bead Luminex assay was used to determine seropositivity for HPV1, -2, and -4 (low-risk skin), -6 and -11 (low-risk mucosal, included in one HPV vaccine), -16 and -18 (high-risk mucosal, included in both HPV vaccines), and -52 and -58 (high-risk mucosal). Health- and behavior-related questionnaires were completed. Type-specific seroprevalence estimates and participant characteristics associated with seroprevalence were calculated; 48% reported HPV vaccination. Type-specific seropositivity in unvaccinated persons ranged from 7 to 21% for skin HPV types and 7 to 38% for mucosal HPV types. Among the unvaccinated participants, adults versus children demonstrated increased HPV1, -6, -16, and -58 seroprevalence of 45% versus 6%, 64% versus 22%, 64% versus 17%, and 36% versus 0%, respectively (all P < 0.05). The vaccinated participants versus the nonvaccinated participants demonstrated increased seroprevalence of HPV6, -11, -16, and -18 of 92% versus 38%, 92% versus 24%, 96% versus 34%, and 75% versus 7%, respectively (all P < 0.0001). Our data demonstrate that the unvaccinated participants had serologic evidence of prior skin and mucosal HPV infections and that seroprevalence increased among adults; in self-reported vaccinees, seroprevalence of HPV vaccine types was 75 to 96%. 相似文献